A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.
Also called NCT01691755
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 196 participants
- Sponsor
- Registry
-
NCT01691755
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Mexico
- Registry status
- Completed
Technical summary
Registry record NCT01691755. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2013-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- aleglitazar
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01691755- Content hash
ee537e5c8dd25b0f6dfe7e4efcf74c8a876cfa1e4edff9ccc30033a9c67fc233